Yuhan has been granted a patent for anti-PD-L1 IgG class antibodies with improved manufacturing yields. The patent covers human antibodies and fragments binding to PD-L1, offering advancements in production efficiency. GlobalData’s report on Yuhan gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Yuhan Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Yuhan, Cancer treatment biomarkers was a key innovation area identified from patents. Yuhan's grant share as of February 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for anti-pd-l1 igg class antibodies

Source: United States Patent and Trademark Office (USPTO). Credit: Yuhan Corp

A recently granted patent (Publication Number: US11919952B2) discloses claims related to polynucleotides encoding antibodies or antibody fragments that bind to a PD-L1 epitope. The antibodies described in the claims consist of specific amino acid sequences for heavy and light chain variable domains, as outlined in the provided SEQ ID numbers. These sequences are crucial for the binding properties of the antibodies to the PD-L1 epitope.

Furthermore, the patent claims cover various configurations of the polynucleotides encoding the antibodies, including different combinations of light and heavy chain variable domains, as well as specific types of antibodies such as IgG1 and IgG4 antibodies. Additionally, the claims extend to fully human antibodies, Fab fragments, and single-chain antibodies. The patent also includes claims related to vectors containing these polynucleotides, emphasizing the importance of these specific sequences in the development of antibodies targeting the PD-L1 epitope. This patent provides a detailed framework for the creation and utilization of antibodies with potential applications in therapeutic interventions targeting PD-L1.

To know more about GlobalData’s detailed insights on Yuhan, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies